- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04658888
St. Joe's Invitation Effectiveness Study
Increasing Cervical Cancer Screening Among Female Patients at Penn State Health St. Joe's Residency Clinic: Letter Notifying Them About Outdated Screen and Postcard With Self-sampling Option
The objective of this study is to evaluate the effectiveness of offering self-sampling for high risk human papilloma virus (HPV) testing in order to increase the number of women who are screened for cervical cancer. The hypothesis of this study is that women who are notified of a need for cervical cancer screening by letter and are also offered a self-sampling kit for cervical cancer screening will have a higher rate of screening than women notified by letter alone.
This study will use an intervention arm (letter and option to request a self-sampling kit) compared to a control arm (letter alone, standard of care) as a reminder that they are out of date for their cervical cancer screening. Women who are out of date with their cervical cancer screening will be identified using the Electronic Medical Record and randomized to the study group in a 2 to 1 ratio (2 for the control arm and 1 to the intervention arm). The primary endpoint that will be evaluated in this study is the method of completion of cervical cancer screening and the use of the self-sampling kit, which will be monitored over a three month period after the letters have been mailed. A secondary endpoint will be the overall rate of cervical cancer screening of all people mailed a letter.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The American Cancer Society estimates that 4,170 women in the United States will die from cervical cancer in 2018. It is possible to prevent many of these deaths through screening and appropriate follow-up in women with positive screens (1). Self-sampling for HPV testing may be a viable option for cervical cancer screening, particularly among women who do not obtain regular screening in a clinical setting.
The objective of this study is to evaluate the effectiveness of offering self-sampling for high risk HPV testing to in order to increase the number of women who are screened for cervical cancer at the Penn State Health (PSH) St. Joseph's family and community medicine residency clinic. This study will use an intervention arm and a control arm. Women in the control arm will receive a standard letter stating that they need to be screened and should contact their primary care provider. Women in the intervention arm will receive a modified version of the letter informing them of a self-sampling option with a pre-addressed post card that allows them to request a self-sampling kit. Once the postcard is returned these women will receive a self-sampling kit in the mail to collect their sample. The kit will come with a pre-paid mailer so that the participant can return their kit for processing at the Penn State Hershey Clinical laboratory.
Women who are out of date with their cervical cancer screening will be identified using the Electronic Medical Record by the use of a set of queries that have been developed to extract this patient population. Eligible women will be randomized to the study group in a 2 to 1 ratio (2 for the control arm and 1 to the intervention arm). The primary endpoint that will be evaluated in this study is the method of completion of cervical cancer screening and the use of the self-sampling kit, which will be monitored over a three month period after the letters have been mailed. A secondary endpoint will be the overall rate of cervical cancer screening of all people mailed a letter. Participants will be recruited continuously until the anticipated sample size has been met. A total of 1,211 participants are expected to participate in this study, 807 in the control arm and 404 in the intervention arm. The study team will calculate the proportion of participants who obtain cervical cancer screening from the clinic or the self-sampling kit and use chi-square tests for statistical analysis.
If a self-collected cervical sample produces a negative result, the participant will be contacted by a study physician with these results. If the sample produces a positive result for low-risk HPV the participant will be contacted by a study physician to schedule a pap test. If the sample produces a positive result for high-risk HPV the participant will be contacted by a study physician for a colposcopy. The pap test and colposcopy are both standard of care for these results. The study team will monitor the completion of the screenings and subsequent procedures.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033
- Penn State College of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Female patients at Penn State Health St. Joe's Family and Community Medicine residency clinic or women's health clinic.
- Ages 30-65 years
- Out-of-date for cervical cancer screening
- Able to speak, read, and communicate well in English or Spanish
- Not greater than average risk for cervical cancer screening
Exclusion Criteria:
- Pregnant
- Incarcerated
- Greater than average risk for cervical cancer (2)
- Have a compromised immune system
- With in-utero exposure to diethylstilbestrol
- Unable to speak, read, and communicate well in English or Spanish
- Unable or unwilling to give implied consent or otherwise complete study requirements
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Modified letter with self-sampling request card
This group will receive a modified letter telling the participant they are out of date with their cervical cancer screening.
They will also receive information on the self-sampling kit and will be provided a card that they can send back to the study team in order to have a kit sent to their house.
The kit will include a pre-paid mailer so that it can be sent back to the lab for testing.
The result will then be shared with the participant.
|
A self-sampling brush to collect cervical cancer cells for screening purposes.
|
No Intervention: Standard letter
Participants will receive a standard of care letter that tells the participant they are out of date with their cervical cancer screening and should contact their primary care provider to schedule an appointment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Cervical Cancer Screening
Time Frame: Three months after the letter is sent.
|
To compare the percentage of cervical cancer screenings completed in the control group who received a standard letter with the percentage of cervical cancer screenings completed in the intervention group who receive a modified letter with a self-sampling option.
|
Three months after the letter is sent.
|
Use of the Self-sampling Kit
Time Frame: Three months after the letter is sent
|
Evaluate the number of participants request and use the self-sampling kit in the intervention group.
|
Three months after the letter is sent
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Rate of Cervical Cancer Screening Over Both the Control and Intervention Group
Time Frame: Three months after the letter is sent
|
Overall rate of cervical cancer screenings for both the control group and the intervention group.
|
Three months after the letter is sent
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Christina Scartozzi, DO, Penn State College of Medicine
Publications and helpful links
General Publications
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018 Jan;68(1):7-30. doi: 10.3322/caac.21442. Epub 2018 Jan 4.
- US Preventive Services Task Force; Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, Doubeni CA, Epling JW Jr, Kemper AR, Kubik M, Landefeld CS, Mangione CM, Phipps MG, Silverstein M, Simon MA, Tseng CW, Wong JB. Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018 Aug 21;320(7):674-686. doi: 10.1001/jama.2018.10897.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 14823
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cervical Cancer Screening
-
Weill Medical College of Cornell UniversityCompletedCervical Cancer Screening | Breast Cancer Screening | Cholesterol Screening | Asthma Admission Rate | Diabetes ManagementUnited States
-
Milton S. Hershey Medical CenterNational Cancer Institute (NCI)CompletedCervical Cancer Screening | Colorectal Cancer ScreeningUnited States
-
Ohio State University Comprehensive Cancer CenterAmerican Cancer Society, Inc.CompletedCervical Cancer | Breast Cancer | Rectal Cancer | Colon Cancer | Abnormal Breast Cancer Screening Tests | Abnormal Cervical Cancer Screening Tests | Abnormal Colon Cancer Screening TestsUnited States
-
Clinical Directors NetworkCompletedDepression | Cervical Cancer Screening | Breast Cancer Screening | Colorectal Cancer ScreeningUnited States
-
Universiti Kebangsaan Malaysia Medical CentreNot yet recruitingCervical Cancer Screening
-
BIOP MedicalUnknown
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR)Completed
-
University of MiamiCompletedHPV Self-Sampling for Cervical Cancer Screening Among Transgender Men and Transmasculine IndividualsCervical Cancer ScreeningUnited States
-
University of MiamiCompletedCervical Cancer ScreeningUnited States
-
City of Hope Medical CenterCompletedCervical Cancer ScreeningUnited States
Clinical Trials on Evalyn Self-Sampling Brush
-
Milton S. Hershey Medical CenterRecruitingCervical Cancer ScreeningUnited States
-
The Institute of Molecular and Translational Medicine...Cancer Research Czech RepublicRecruitingCervical Cancer | Human Papillomavirus Infection | Cervical DysplasiaCzechia
-
Milton S. Hershey Medical CenterTerminated
-
University of AarhusAarhus University Hospital; Bandim Health Project; Universiteit Antwerpen; Randers...RecruitingHIV Infections | Cervical Cancer | HPV-Related Cervical Carcinoma | Coinfection, HIVGuinea-Bissau
-
University Hospital, LilleMinistry of Health, FranceCompletedCervical Intraepithelial Neoplasia | Malignant Tumor of CervixFrance
-
The Institute of Molecular and Translational Medicine...Cancer Research Czech RepublicCompletedCervical Cancer | Human Papillomavirus Infection | Cervical DysplasiaCzechia
-
Institut d'Investigació Biomèdica de BellvitgeInstitut Català d'Oncologia; Institut Català de la Salut; Complejo Hospitalario...RecruitingCervical Cancer Screening | HPV-Related Cervical Carcinoma | Self-samplingSpain
-
George Washington UniversityNational Cancer Institute (NCI)RecruitingCervical Cancer | Human Papilloma Virus | CIN 2/3United States
-
Milton S. Hershey Medical CenterTerminated
-
SciensanoHorizon 2020 - European CommissionRecruiting